Ironwood Delivers $0.24 EPS in Q1, Tops Estimates After Prior-Year Loss
IRWD•Ironwood Pharmaceuticals delivered first-quarter earnings of $0.24 per share, outperforming the consensus estimate of $0.07 and swinging from a $0.14 per share loss a year earlier. Revenue also exceeded consensus estimates.
1. Q1 Earnings Beat
Ironwood Pharmaceuticals reported first-quarter earnings of $0.24 per share, beating analyst forecasts of $0.07 by $0.17 and marking its first profitable quarter since the prior year.
2. Revenue Exceeded Estimates
Total revenue for the quarter surpassed consensus projections, reflecting solid uptake of the company’s marketed therapies across its gastrointestinal portfolio.
3. Turnaround from Prior-Year Loss
The company reversed a $0.14 per share loss from Q1 last year, driven by improved cost controls and increased sales volume in its core product lineup.
